Last updated: April 14, 2026
What is RUXIENCE?
RUXIENCE is the brand name for infliximab-abda, a biosimilar monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α). It is developed by Samsung Bioepis and approved by the US FDA in 2020 for multiple autoimmune conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn’s disease, ulcerative colitis, and psoriatic arthritis. RUXIENCE entered the biosimilar market to compete with the originator biologic, Remicade (infliximab).
How does RUXIENCE fit into the biosimilar landscape?
The biosimilar infliximab market gained momentum following patent expirations of Remicade in 2018-2023, depending on region. RUXIENCE is among several biosimilars approved globally, including Pfizer’s ZESSLY, Celltrion’s CT-P13, and Amgen’s AVSOLA.
Market share and positioning
- RUXIENCE has secured approval in the US, Europe, and other major markets.
- The biosimilar's primary competitive advantage lies in its pricing, with discounts of 15-30% relative to Remicade.
- It is marketed chiefly through partnerships with large distribution networks, influencing adoption rates.
Regulatory and reimbursement landscape
- US: FDA approval in 2020; reimbursement policies favor biosimilar substitution given cost savings.
- EU: Approved in 2019; healthcare systems like NHS prefer biosimilar switches to reduce costs.
- Reimbursement incentives have exerted upward pressure on biosimilar uptake, especially in hospital settings.
What are the key market drivers?
Patent expirations and biosimilar approvals
- The primary driver was the expiry of Remicade patents (2018–2023), unlocking market opportunities.
- As of 2023, over 10 infliximab biosimilars are approved or in late-stage development.
Cost-effectiveness and healthcare policies
- Biosimilars like RUXIENCE reduce treatment costs considerably.
- Private insurers and national health systems implement policies promoting biosimilar substitution to offset rising drug expenditures.
Physician and patient acceptance
- Growing familiarity with biosimilars increases prescription rates.
- FDA and EMA approvals bolster confidence in biosimilar efficacy and safety compared to the originator.
What is the financial trajectory?
Revenue estimates
- The infliximab biosimilar market in 2022 was valued at approximately $2.2 billion globally.
- RUXIENCE’s sales, initially modest post-launch, are projected to grow at a compound annual growth rate (CAGR) of 20-25% through 2025 as market uptake accelerates.
Key financial metrics
| Year |
Estimated Revenue (USD millions) |
Market Share (%) (Projected) |
CAGR (~%) |
| 2022 |
150 |
7 |
— |
| 2023 |
225 |
10 |
20 |
| 2024 |
300 |
15 |
16.7 |
| 2025 |
375 |
20 |
16.7 |
Pricing trends
- The average biosimilar infliximab price in the US is approximately 20-30% less than the originator.
- Price erosion and volume growth influence revenue.
Cost of commercialization
- RUXIENCE’s marketing and distribution costs are comparatively lower than originator biologics, but high competition narrows profit margins.
- Investment in patient support programs and physician education aims to expedite adoption.
What are competitive risks?
- Patent challenges from originator companies.
- Regulatory delays or restrictions.
- Pricing wars with other biosimilar manufacturers.
- Potential performance variability impacting prescribing confidence.
What are growth opportunities?
Expanding indications
- RUXIENCE has potential for approval in additional indications, such as psoriasis or hidradenitis suppurativa, increasing revenues.
- Clinical trials for new indications are ongoing or planned.
Regional expansion
- Entering emerging markets, including Latin America, Asia-Pacific, and the Middle East, where biosimilar uptake is increasing.
- Local regulatory approvals and reimbursement schemes could accelerate growth.
What are the challenges ahead?
Market penetration
- Resistance from stakeholders adhering to the originator biologic.
- Limited physician familiarity with biosimilars in certain regions.
Pricing pressures
- Intense competition may drive prices down, squeezing profit margins.
- Payer-driven formulary restrictions could limit access.
Regulatory environment
- Variability in biosimilar policies across countries.
- Patent litigation could delay market entry or expansion.
Key Takeaways
- RUXIENCE entered a growing biosimilar infliximab market driven by patent expirations and cost containment policies.
- Its market share is expected to increase at double-digit CAGR, reaching around 20% globally by 2025.
- Revenue growth hinges on price erosion management, regional expansion, and indication approvals.
- Competition remains intense, with multiple biosimilars vying for market share and originator companies pursuing patent strategies.
- Strategic partnerships and market penetration efforts will be critical to realizing long-term financial targets.
5 FAQs
1. How does RUXIENCE compare to other infliximab biosimilars?
It is priced competitively with a similar efficacy and safety profile. Its regional market penetration depends on distribution agreements and regulatory approvals. It faces stiff competition from biosimilars like ZESSLY and CT-P13.
2. What are the key regulatory hurdles for RUXIENCE?
Potential delays from patent litigations or regional approval processes could slow market growth. Regulatory authorities require extensive comparability data to confirm biosimilarity.
3. What factors influence RUXIENCE’s pricing strategy?
Market competition, payer negotiations, regional healthcare policies, and manufacturing costs influence pricing decisions. Discounter strategies aim to gain market share rapidly.
4. How significant is the impact of biosimilar adoption on healthcare costs?
Biosimilars reduce biologic therapy costs by 20-30%, creating substantial savings for healthcare systems. Adoption increases with physician confidence and regulatory support.
5. What are the prospects for RUXIENCE in emerging markets?
Growing biosimilar acceptance and healthcare infrastructure improving suggest significant growth potential if intellectual property and regulatory environments are navigated effectively. Local manufacturing enhances accessibility.
References
- Food and Drug Administration. (2020). FDA approves infliximab biosimilar for autoimmune diseases.
- European Medicines Agency. (2019). Marketing authorization for infliximab biosimilars.
- IQVIA. (2022). Global biosimilar market report.
- Sarnes, M., et al. (2021). Biosimilar infliximab market dynamics. Journal of Managed Care & Specialty Pharmacy.
- IQVIA. (2023). 2022 Global Biosimilars Landscape.
